Your browser doesn't support javascript.
loading
Smoking cessation by combined medication and counselling: a feasibility study in lung cancer patients.
Reinhardt, Christian; Harden, Markus; Herrmann-Lingen, Christoph; Rittmeyer, Achim; Andreas, Stefan.
Afiliación
  • Reinhardt C; Lungenfachklinik Immenhausen, Immenhausen, Germany.
  • Harden M; Institute of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
  • Herrmann-Lingen C; Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.
  • Rittmeyer A; Lungenfachklinik Immenhausen, Immenhausen, Germany.
  • Andreas S; Department of Cardiology and Pneumology, Member of the German Center for Lung Research (DZL), University Medical Center Göttingen, Robert-Koch-Str. 40., Göttingen, Germany.
BMC Pulm Med ; 22(1): 252, 2022 Jun 27.
Article en En | MEDLINE | ID: mdl-35761222
ABSTRACT

PURPOSE:

Smoking cessation in patients with diagnosed lung cancer has positive effects on cancer therapy and overall prognosis. Despite this, knowledge on smoking cessation in lung cancer patients is sparse.

METHODS:

This is an observational single centre, 12-week, prospective, single-arm trial at a tertiary lung cancer centre. Responsive patients were enrolled following confirmed lung cancer diagnosis. Smoking cessation intervention included counselling as well as pharmacotherapy. The primary endpoint was the point prevalence abstinence rate at week 12 based on biochemical verification. Secondary endpoints were the abstinence rate at week 26, quality of life and side effects.

RESULTS:

80 patients were enrolled. Mean age was 62.6 ± 7.9 years. Most patients (63%) were treated with chemotherapy or radiochemotherapy. 39 patients used nicotine replacement therapy, 35 varenicline whereas six patients did not use pharmacotherapy. During the study period 13 patients died. Data were available in 72 patients after 12 weeks and 57 patients at week 24. Point prevalence abstinence rates were 37.5% (95% CI 26.4-49.7%) at week 12 and 32.8% (95% CI 21.8-45.4%) at week 26, respectively. Quality of life and side effects were not significantly affected by pharmacotherapy.

CONCLUSION:

In conclusion, our results suggest that smoking cessation is feasible in patients with newly diagnosed lung cancer. The observed abstinence rate is comparable to other patient cohorts. Furthermore, pharmacotherapy in addition to cancer therapy was safe and did not show novel side effects in these seriously ill patients. Thus, smoking cessation should be an integral part of lung cancer treatment. Trial registration The study was conducted in accordance with good clinical practice standards (GCP) and approved by the local ethics committee (16/3/14), the European PAS registry (EUPAS8748) and the German BfArM (NIS-Studien-Nr. 5508). All patients provided written informed consent before study enrollment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cese del Hábito de Fumar / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Aged / Humans / Middle aged Idioma: En Revista: BMC Pulm Med Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cese del Hábito de Fumar / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Aged / Humans / Middle aged Idioma: En Revista: BMC Pulm Med Año: 2022 Tipo del documento: Article País de afiliación: Alemania